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Abstract
Most patients with ovarian cancer (OC) have the epithelial subtype (EOC) and present
with advanced stage disease. Despite improved surgical and medical management of
primary disease, the majority of patients will develop recurrence and ultimately die of
disease. The current surgical goal in primary EOC is complete surgical cytoreduction
(CSC) as this significantly improves disease-specific survival and overall survival.
CSC is a major independent prognostic factor in primary EOC. Recurrent ovarian
cancer (ROC) can be diagnosed in the symptomatic or in the asymptomatic patient
on clinical evidence, tumour marker results and/or imaging. There are data from cases
series and retrospective series on the role of surgery in ROC but there is not yet level I
evidence of secondary surgical cytoreduction improving overall survival. The
published data emphasise that, as with primary disease, the surgical goal is CSC. In
selecting patients for secondary cytoreductive surgery a number of predictive models
have been proposed and tested. Patients with ROC who have undergone CSC have a
better prognosis than those treated with chemotherapy alone or those in whom the
surgical goal was not achieved. The counter-argument is that there is bias in the
surgical reports—those patients not operated on chemotherapy alone, or who had
incomplete cytoreduction and/or who had chemotherapy had less favourable disease-
associated and patient-associated factors than those who had CSC. To address these
concerns, there are currently three ongoing randomised controlled trials on surgery
for ROC.
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1. Introduction
The hallmarks of cancer include (1) the potential for dissemination of cancer cells to adhere to
distant sites and establish tumour growth—metastases and (2) the potential to recur following
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primary or subsequent treatments. Frequently these develop together and herald relentless
progression until the patient succumbs to disease. For all cancers, these processes show a
greater propensity with higher stage (or TNM) of disease at presentation. Furthermore, it is
known that certain types or subtypes of a given cancer have a greater or lesser tendency to
metastasise and recur than others.
The typical clinical picture of ovarian cancer (OC) is presentation with advanced stage disease
in the post menopausal woman and despite advances in medical and surgical treatments, most
patients will die of disease. While arguably the goal of primary treatment is cure, this applies to
those with early stage disease but not for all subtypes. Data from CRUK [1] show that there
were 7378 new cases of OC and 4128 deaths from OC in 2014. These deaths were in most cases
due to recurrent disease rather than primary disease. Survival is also associated with lower
patient age and the overall 5-year survival is about 35%; the 5-year survival for stages III and
IV disease is about 20 and <5%, respectively [1]. The majority of data on ovarian cancer is based
on epithelial ovarian cancer (EOC) and this review predominantly deals with recurrent EOC.
2. Defining recurrent cancer
This is the detection of the cancer following a period of time after completion of primary
treatment. The NCI Dictionary of Cancer terms [2], defines recurrent cancer as “Cancer that
has recurred (come back) after a period of time during which the cancer could not be detected”.
This is vague and open to interpretation and in clinical practice requires more careful scrutiny:
1. How undetectable disease is defined at the end of primary treatment and how recurrence
is defined?
2. How the recurrent disease is detected—clinically, by tumour marker(s), radiologically?
3. The time intervals in the follow-up of patients, the methods of surveillance and how often
these are used.
4. Whether there is a clear distinction between persistence of disease following primary
treatment and recurrence.
For example, a unit that regularly scans patients after primary treatment may detect evidence of
recurrent disease sooner than a unit which relies on serial tumour markers. Indeed, 2 units may
use imaging as part of surveillance but one unit may scan more often that another, or measure
tumour markers more frequently than another. Complicating this further is that not all recur-
rences are associated with rising tumour markers and different modalities of imaging have
differing sensitivities and specificities in detecting early or small volume recurrent disease.
Compounding the understanding of the role of, and efficacy of, different managements for
recurrent disease is tumour and patient heterogeneity [3]. As a consequence, caution needs to
be given to the interpretation of data on the efficacy of different managements of recurrent cancer
—including the role of surgery in recurrent ovarian cancer (ROC). Trial design and the endpoints
of trials have important implications [3–5]. It is generally accepted though that overall survival
(OS) is the most clinically relevant and the most clearly definable endpoint [3]. Modern imaging
and tumour makers have replaced what was the common practice of second look laparotomy
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(SLL) in OC, which is no longer recommended. Unlike most other recurrent gynaecological
cancers where typically histologic confirmation of recurrence is required before treatment, this
is the exception in cases of ROC.
Essentially all OC patients receive platinum-based chemotherapy as part of primary treatment
and some concepts are used to help stratify and compare managements of recurrent cancer.
These include (1) platinum-sensitive and platinum-resistant disease [6] and (2) platinum-free
interval (the interval between date of last platinum dose and date of relapse, PFI) and (3) progres-
sion-free survival (PFS). The definition of platinum sensitive and platinum resistant is somewhat
arbitrary, but clinically useful. There is an argument that surgical trials might instead focus on
date of last treatment (treatment-free interval (TFI)), and date of last operation rather than
response to platinum or PFI [7]. Platinum-sensitive OC is defined as disease that is undetected at
completion of primary treatment with platinum and which is undetectable for at least 6 months
after completion of platinum-based chemotherapy; platinum-resistant disease is ovarian cancer
that is detected within 6 months of completion of platinum-based chemotherapy. Other terms
used in reports on recurrent cancer are time to first subsequent treatment and intervention-free
interval. It is not clear what impact the use of maintenance therapy as an extension of primary
treatment will have on these definitions.
3. Determination of recurrent ovarian cancer
Recurrence is documented clinically, and/or by tumour marker levels and/or radiologically
and in different clinical units the policy of post-treatment surveillance is variable. The clinical
determination of relapse may be in an asymptomatic or symptomatic patient, and rarely OC
patients may present acutely, for example, with bowel obstruction. Indeed, previously treated
OC patients who develop bowel obstruction almost always have (recurrent) disease as the
cause, even if this is not suspected on tumour marker levels or on imaging.
3.1. Clinical features
Recurrence may be suspected from the patient’s history—symptoms include weight loss,
weight gain (e.g. from ascites), leg swelling (unilateral or bilateral), dyspnoea, pelvic pressure
symptoms and loss of appetite. More unusual symptoms relate to the paraneoplastic syn-
drome including features associated with hypercalcaemia, myositis, erythema nodosum and
herpes zoster. Less commonly patients have haematuria, vaginal or rectal bleeding. The patient
may of course be asymptomatic.
The clinical examination, which should include assessment of the lymph nodes, abdominal
and pelvic examination and recto-vaginal examination, may be normal. If the patient presents
more acutely, for example with dyspnoea or evidence of bowel obstruction, there are usually
concerning clinical findings.
3.2. Blood results
Unless clinically indicated, the usual test off treatment is to measure the serum tumour marker(s).
The evidence that this is useful clinically and contributes to more efficacious treatment and
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improved prognosis has been challenged [8, 9]. With regard to the common EOC, recurrent
disease may not be associated with high levels of CA 125, it may be associated with a normal
level or with a rise within the normal range, and there are other non-cancer explanations for a
rising level post-treatment. In a recent trial, it was concluded that treating recurrences (early)
with chemotherapy based on rising tumour marker(s) was not associated with increased
survival but was associated with a reduced quality of life [8–10]. It is important to note,
however, that secondary cytoreductive surgery was not a standard of care in this trial. On the
other hand, there is some evidence that early surgical intervention in asymptomatic patients
might increase the rate of complete secondary cytoreductive surgery [11, 12]. This then is an
argument for post-treatment surveillance by serial tumour marker estimations. With a rise in
CA125 noted, the median time to clinical evidence of relapse is 2–6 months. There are no
national guidelines in the UK regarding the post-treatment use of serial assessment of serum
markers which is often to allay patient anxiety or as part of a trial protocol. Likewise in the
USA, the national society, Society of Gynecologic Oncologists (SGO) [13], has not unequivo-
cally endorsed routine post-treatment surveillance using serum tumour marker(s).
3.3. Imaging
In 2000, a collaboration of major cancer groups published criteria to help standardise radio-
logic interpretation of response to treatment of disease (cancer), which are known as Response
Evaluation Criteria in Solid Tumours (RECIST) [14]. In the non-acute routine clinical follow-
up, there is variation in the use of imaging, the modality used and the frequency of imaging.
Patients on clinical trials typically will have regular imaging as part of the trial. There are no
national guidelines in the UK. The National Comprehensive Cancer Network (NCCN) does
not stipulate or recommend routine imaging after primary treatment of OC [15]. In most
centres, imaging will be performed if there are symptoms (e.g. weight loss, abdominal disten-
sion) or signs (palpable pelvic mass). In the UK, the usual imaging will be a CT scan of chest
abdomen and pelvis; in other centres FDG-PETmay be performed instead of, or in addition to,
CT. Practices also vary in the timing of imaging in relation to rising serum tumour marker(s)—
including rising levels within the normal range, and levels that exceed the normal range.
However, as noted above, early treatment of recurrence with chemotherapy is reportedly not
in the patient’s best interest whereas earlier surgical intervention may be [8, 9, 11, 12]. In the
symptomatic patient with, for example, suspected bowel obstruction, a number of imaging
tests will be performed in an effort to confirm the diagnosis, to determine the cause, and to aid
in the management decisions.
When deciding on the management of a patient with ROC whose initial management has been
in another institution, in many cases it is recommended that there be a review of histology and
relevant imaging, and details of the prior surgery. The operative reports should be obtained
rather than reliance on a brief summary in patient correspondence.
4. Surgical considerations in the patient with ROC
A general impression is that secondary cytoreductive surgery for ROC is more commonly
routine practice in the USA and parts of Europe, and less so in the UK. This is evidenced by the
Ovarian Cancer - From Pathogenesis to Treatment274
fact that most reports on the role or impact of such surgery have come from non-UK centres.
Almost all reports on surgery for ROC refer to recurrent EOC and not to the non-epithelial types
or borderline cancers. Furthermore, the reports on surgical management mostly focus on the first
recurrence after primary treatment, rather than the second or third recurrence. The NCCN
Guidelines [15] state that secondary cytoreduction can be considered in patients with recurrent
ovarian cancer (1) (detected at) more than 6–12 months after completion of initial chemotherapy,
(2) who do not have ascites and (3) who have an isolated recurrence (or few foci) of disease
which can be completely resected.
In clinical practice, there are different scenarios in which the surgical option for ROC needs to
be considered.
Broadly these may be described as:
1. Recurrent ovarian cancer with pelvic and/or abdominal disease (including retroperitoneal
lymph nodes); the patient may asymptomatic or symptomatic.
2. Surgery and intraperitoneal chemotherapy (IP) or heated intraperitoneal chemotherapy
(HIPEC) for recurrent cancer.
3. Recurrent ovarian cancer outside the pelvis and abdomen.
4. Recurrent ovarian cancer and bowel obstruction.
5. Further recurrence in patients previously operated on or treated for recurrence.
6. Recurrent non-epithelial ovarian cancer (borderline tumours are discussed elsewhere).
There are many published reports on the role and impact of secondary cytoreductive surgery
in ROC. Many are from single institutions, often with small numbers, and with minimal
quality of life data and, as yet, there are no published studies providing level I evidence on
the impact of secondary cytoreductive surgery on overall survival in ROC. So although the
best evidence at present is not yet confirmed in trials, there are three randomised controlled
trials assessing the role of surgery in ROC, only one of which has just released preliminary
data. These are DESKTOP III, SOCceR and GOG 213, in all of which an eligibility criterion is
platinum-sensitive EOC [16–18].
a. DESKTOP III Trial: This follows on from the DESKTOP I and II trials and again the predic-
tive model is the positive AGO score for complete secondary surgical cytoreduction. In this
trial, two groups are compared—chemotherapy only group and cytoreductive surgery
followed by chemotherapy group.
b. SOCceR Trial: This Dutch trial is of secondary CRS and chemotherapy compared to
chemotherapy alone in recurrent disease. The primary endpoint is PFI.
c. GOG 213 Trial: In this trial after randomisation to cytoreductive surgery (CRS) patients
are then randomised to one of four treatment arms, two of which contain bevacizumab.
Assessing surgery in ROC involves considering the can do/should do approaches and the best
to worse scenario from surgery; allied considerations include the timing of surgery, the goal of
surgery, morbidity and mortality from surgery and impact on quality of life issues (QoL). From
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the patient’s perspective when deciding on major surgery, the main considerations are whether
there are symptoms or not, the impact of surgery on symptoms and on survival, morbidity and
mortality from surgery, quality of life issues (QoL), and response to further chemotherapy or
other agents. It is more often easy to decide who not to operate on electively for recurrent
disease. This decision is based on disease-associated and patient-associated factors. The former
include—disease-free interval, platinum-sensitive/platinum-resistant disease, histology, site or
sites of recurrent disease, with and without ascites; the latter include whether the recurrence is
symptomatic or asymptomatic, QoL and performance status. There are also surgeon-related
factors which relate mostly to the surgical philosophy in the management of recurrent disease
—in essence whether to operate on the asymptomatic patient or not, and whether to remove
bulk disease only or to plan to achieve complete surgical cytoreduction (CSC) where at end
of surgery there is no gross visible disease. As will be discussed, the evidence is very much
in favour of CSC to maximise patient benefit as defined by overall survival. The surgeon
and/or other members of the oncology team also need to discuss the treatment alternatives
with the patient.
4.1. Patient selection criteria for secondary cytoreductive surgery
Major surgery for recurrent ovarian cancer is associated with morbidity and mortality—
reportedly from minimal up to 88.8 and 5.5%, respectively [19]. Given the heterogeneity in
the patient population and the variation in surgical practice, this perhaps is not surprising.
However, it also attests to lack of appropriate reliable criteria for case selection. The goals for
elective surgery for recurrent disease in the abdomen/pelvis are to (1) improve overall survival,
(2) minimise surgical morbidity and (3) improve QoL. The data on QoL following secondary
surgical cytoreduction are, however, sparse.
The rationale for surgery might be considered as an extension of the surgical philosophy in the
management of primary ovarian cancer—that complete surgical cytoreduction and combina-
tion chemotherapy provides the best therapy to achieve increased overall survival. Further-
more, in the setting of recurrent disease and the known poorer response of ovarian cancer to
second-line therapy compared to first-line therapy, one can argue that cytoreduction may have
a more important role in recurrent cancer. Indeed, most of the evidence on clinical trials in the
chemotherapy-only approach to ROC report median survival of about 18 months in platinum-
sensitive disease and about 12 months in platinum-resistant disease [20]. Patients with ROC
who undergo CSC have improved survival compared to those treated with chemotherapy
alone, but selection bias is likely as those unfit for surgery, for example, will most often receive
chemotherapy.
Repeatedly studies report that overall survival is improved with surgical cytoreduction in
patients with platinum-sensitive disease but only in patients with CSC and in those with
minimal residual disease. In essence the surgical goal in regard to cytoreduction for first
recurrence is the same as for primary disease—complete resection. From these studies, a
number of factors emerge which are associated with improved survival (Table 1). These
factors are not dissimilar to those reported as important factors in improved outcome from
chemotherapy for ROC [21, 22]. What is less clear from the reports is how much weight to
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place on each factor in each individual case. Intuitively one would consider that long disease-
free interval, good performance status (before elective surgery) and complete surgical
cytoreduction would be favourable for improved survival. A number of predictive models
been proposed to improve case selection for secondary complete cytoreductive surgery as
these patients benefit most from surgery (Tables 2 and 3).
The original DESKTOPOVAR I trial which involved 25 institutions (Arbeitsgemeinschaft Gynae-
kologische Onkologie [AGO] Descriptive Evaluation of preoperative Selection (K) Criteria for
Operability in recurrent ovarian cancer trial) reported that the main predictor for overall survival
was complete surgical resection, which was achieved in 49.8% of patients [23]. Patients with non-
epithelial ovarian cancer, those with low malignant potential tumours, and those undergoing
palliative surgery (as opposed to cytoreductive surgery) were excluded [23]. In the subsequent
DESKTOP I Trial [24], in patients with platinum-sensitive disease, the authors reported a median
survival of 45 months compared to 19 months in those with complete and incomplete surgical
resection, and those (in other studies) treated with chemotherapy alone. Of interest, they also
reported that peritoneal carcinomatosis was not a negative factor if complete resection was
achieved emphasising that carcinomatosis was not a contraindication to surgery and that com-
plete resection despite the presence of carcinomatosis improved survival [24]. From this study,
three prognostic factors for complete resection were identified: (1) good performance status
(defined as) on the ECOG criteria [25] (European Cooperative Oncology Group), (2) complete
resection at first surgery for primary disease and (3) ascites volume less than 500 ml. These were
grouped as the AGO score and defined as positive if all three were present. These were subse-
quently validated in the DESKTOP II study [26]. It is of interest that imaging was relevant to
their predictive model only for measuring volume of ascites and not for the number, size or
anatomic location of tumour recurrences. Intuitively it might be considered that carcinomatosis
in the setting of recurrent disease would be a contra-indication to secondary surgery and that
resection of such disease would not improve overall survival. Laparoscopic assessment was not
Primary disease
Initial FIGO stage (early versus late)
Residual disease after primary surgery (complete vs. incomplete)
Disease-free interval (platinum-sensitive, platinum-resistant)
Platinum-free interval
Recurrent disease
Performance status
Number of sites of recurrence
Ascites (present or absent (or <500 ml))
Serum CA 125
Tumour burden/largest tumour mass
Initial second-line chemotherapy before secondary surgery (yes/no)
Table 1. Prognostic factors for improved survival after cytoreductive surgery for ROC.
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part of the protocol. There is some suggestion that open laparoscopy may help in case selection
—Plotti et al. [27] reported 34 of 38 patients who had a laparoscopy suggesting suitability for
surgery subsequently underwent complete secondary cytoreduction. Although there are some
randomised data on the use of laparoscopy to determine complete surgical cytoreduction in
primary EOC, there are no such data for recurrent disease [28, 29].
A subsequent analysis based on pooled data from an international collaborative cohort [30]
reported a scoring system ranging from 0 to 8: progression-free interval < 23.1 months (2), ascites
(1), multiple sites of recurrence (1), residual disease after secondary cytoreductive surgery
AGO Score [23, 24]
1. Complete surgical cytoreduction at primary surgery
2. Absence of ascites at recurrence (<500 ml)
3. ECOG performance status ≤1
Tian Scoring System [33]
1. Initial stage
2. Residual disease after primary cytoreductive surgery
3. Progression-free interval
4. CA 125 at recurrence
5. Presence of ascites at recurrence
6. Performance status
SeC-Score [34]
1. CA 125 at recurrence
2. HE4 at recurrence
3. Presence of ascites
4. Residual tumour volume at completion of primary surgery
Minaguchi Proposal [37]
1. TFI >12 m (versus < 12 m)
2. No distant metastases (versus distant metastasis)
3. Single versus more than one site of recurrence
4. PS 0
Memorial Sloan Kettering Proposal [40, 41]
1. Time to recurrence (DFI)
2. Single or more than one site of recurrence
3. Presence or absence of carcinomatosis
• DFI 6–12 m surgery for single site recurrence, possibly if more than one site
• DFI 12–30 m surgery for one or more sites of disease; possible surgery if carcinomatosis
• DFI > 30 m surgery for single site, multiple sites, and carcinomatosis
Table 2. Predictive models for complete surgical Cytoreduction in recurrent ovarian cancer (based on platinum-sensitive
disease).
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[none, 0.1–1 cm (2): >1 cm (4)]. Low and high-risk models were defined. The difference in median
survival between the two groups (63.0 and 19.1months) was highly significant, and they reported
that complete surgical resection was the goal if survival gain was to be maximised. Their model,
however, is arguably not straightforward. Note is made that the results of imaging had more
influence on decision making (ascites and number of sites of disease) than in the AGO predictive
model. In contrast, other studies have reported an improved outcome with single site versus
multiple site recurrence [31] and with a DFI of 24 months or more [32].
Tian et al. [33] reported on another model in an attempt to better define those patients with
recurrent disease most likely to benefit from cytoreductive surgery. Six criteria were identified—
initial FIGO stage, residual disease after primary cytoreduction, progression-free interval, ECOG
performance status, CA125 and ascites. They categorised patients into low and high-risk groups
based on the score. Compared to other models they reported lower complete cytoreduction rates
(53.4% in the low risk group and 20.1% in the high-risk group) than in DESKTOP I. Another
group proposed another model which they defined as the SeC-score using four criteria [34]: pre-
operative CA 125, pre-operative HE4, ascites and residual disease at primary surgery. They
reported a sensitivity and specificity of 82 and 83%. This is one of the few reports to comment
on the potential value of CA125, and in a previous study an elevated CA 125 was reported as a
negative prognostic factor [35]. Angioloi et al. were the only group reporting on the newer
tumour marker, HE4, and the only one in which performance status was not considered. Again
in this model, as in the AGO model, the role of pre-operative imaging was essentially only to
measure the volume of ascites. Frederick et al. [36] reported in a study on 62 patients with prior
complete cytoreduction and platinum-sensitive disease that the only pre-operative factor
predicting prolonged survival was a CA125 of less than 250 U/ml which was associated with
complete surgical cytoreduction. A Japanese group proposed another model using four criteria
[37]—treatment-free interval > 12 months, single site disease, absence of distant metastasis(es)
and performance status of 0. Depending on the number of favourable factors, the outcome in
terms of complete resection, and overall survival were significantly different.
Primary disease
Early FIGO stage
Complete cytoreduction at primary surgery
Long DFI/PFI
Recurrent disease
Good performance status
No ascites
Number of sites of recurrence**
Maximum tumour dimension
CA125***
*Based on data from platinum-sensitive epithelial ovarian cancer.
**The fewer the better the outcome.
***Normal versus abnormal level.
Table 3. Predictive factors for complete surgical cytoreduction (CSC) in ROC*.
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A number of studies have assessed the two most used predictive models—that proposed by
Harter (AGO) and that proposed by Tian [23, 33]. Janco et al. [38] reported that although a
positive AGO score was predictive of complete SCR in 79% of patients, in 64.4% of AGO
negative cases complete SCR could also be achieved—and as such the AGO score was not
an independent factor associated with improved survival. Similar findings of complete
cytoreduction—high positive predictive value and high false negative rates—were reported for
both models in a population based study on Dutch patients [39]. In this study, 48% of patients
had had chemotherapy before surgical cytoreduction but this did not impact on their results.
Following on from an earlier proposal for surgical resection in ROC [40], the Memorial Sloan
Kettering group compared their scoring system to the AGO and the Tian models in identifying
those patients likely to benefit from secondary cytoreductive surgery—that is, those patients in
whom complete surgical resection is more likely to be achieved. They proposed to offer second-
ary cytoreductive surgery to those with: (1) a disease-free interval of less than 6 months, if there
was single site disease, (2) disease-free interval of 12–30 months, even if multiple sites of disease
provided there was no carcinomatosis and (3) those with carcinomatosis, if the disease-free
interval was more than 30 months. These selection criteria might be considered to be counter-
intuitive and are different to those of previous reports, but their assessment of the impact of
carcinomatosis, is similar to that of the DESKTOP I study, albeit in the context of a longer DFI.
They reported [41] that their model was more predictive of complete resection than either the
AGO or Tain model. A study from two French centres [42], where initial laparoscopic assessment
was common, both the AGO and Tian models were used to evaluate patients; they reported high
positive predictive values for complete cytoreduction (80.6 and 74%, respectively, for each
model) yet high false negative values (65.4 and 71.4%, respectively).
It can been seen than that although various models have been proposed with some common
criteria, the more commonly used AGO and Tian models are associated with significant false
negative predictions. It is of no surprise that the factors associated with improved survival in
ROC and factors associated with increased rate of CSC in ROC, are similar (Tables 1 and 3).
Perhaps surprising is that in most series pre-operative CA125 is not considered relevant. Most
studies do not report on or recommend an initial laparoscopic assessment, a procedure not
without risks, limitations and the associated logistic problems of planning operating lists. Other
than Eisenkop’s early reports [43, 44], it is also surprising that in most other later models
determining and evaluating criteria for surgery of ROC, tumour volume or size of recurrence
were not considered relevant. An exception is the report by Onda et al. [45] in which size of
recurrent disease or tumour burden was an important factor in case selection. While much
emphasis has been given to the importance of complete resection in primary EOC and the
positive impact on survival, some reports have emphasised that initial tumour burden in pri-
mary disease limits the gains from such surgery—the argument again about surgical skill and
tumour biology [46–48]. If indeed tumour burden is important in primary disease, arguably it
should be of similar if not more importance in recurrent disease, where chemotherapy is less
effective. Furthermore, it is quite clear that patients treated for primary EOC by gynaecological
oncologists who achieve CSC have an improved outcome when the cancer recurs, compared to
patients in whom primary surgery was incomplete. The positive effects of optimum treatment of
primary EOC, continue through recurrent disease. Quite evidently, the characteristics of primary
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disease and its management (e.g. complete versus incomplete surgical cytoreduction) have a
major impact on the surgical decision making for recurrent disease.
Most recently the preliminary results of one of the RCTs on secondary cytoreductive surgery
for recurrent ovarian cancer, DESKTOP III, have been reported in an abstract at the 2017
meeting of ASCO [49]. These were that (1) complete resection was achieved in 67% of patients,
(2) there was an increase in PFI (14 months versus 19.6 months), (3) an increase in time to
first subsequent treatment (TFST) (13.9 months and 21 months) and (4) data on OS are
immature.
5. SCS in platinum-sensitive recurrent ovarian cancer
There are now numerous reports on secondary cytoreductive surgery (SCS) for recurrent
ovarian cancer, with the focus on the epithelial subtype. They consistently show a benefit in
overall survival—that is in ROC, complete surgical cytoreduction (with or without subsequent
chemotherapy) is superior to chemotherapy only in these patients. The counter-argument is
that the cases selected for surgery have more favourable features than those treated with
chemotherapy alone. But as with primary disease, there is a subgroup who will not undergo
surgery and be treated with chemotherapy alone, or rarely palliative care only. These treatment
options should not be seen as competing for patients or as an either/or dilemma but as part of
the multi-disciplinary team decision as to what is the best management for a particular patient.
The initial report by Berek et al. [50] on ROC showed a survival benefit where the surgical result
was optimal (<1.5 cm residual) compared to suboptimal. In a later small study on 36 patients
Eisenkop, and a subsequent study by the same authors on 106 patients [43, 44] reported a
survival benefit from cytoreduction which was compromised by prior second-line chemother-
apy before secondary cytoreductive surgery and where the tumour burden (maximum tumour
diameter) was large (>10 cm). Their reports are unusual in that most other reports do not
consider either factor as important in case selection for SCS. They also reported that the key
surgical factor improving overall survival was complete cytoreduction. Other reports have
found the same association and reported [51] that chemotherapy before surgical cytoreduction
had a negative impact on surgery.
A common intraoperative finding in recurrent disease is carcinomatosis, which is most prob-
lematic where there is extensive involvement of the small bowel serosa and/or mesentery and
often results in incomplete surgical cytoreduction. However, the DESKTOP I and II trials
reported that even with carcinomatosis, if complete surgical clearance is achieved, carcinoma-
tosis is not a negative prognostic factor in recurrent disease. Indeed, Chi et al. also consider
that carcinomatosis is not a contra-indication to secondary cytoreductive surgery if the disease-
free interval is 30 months or more as there is patient benefit if CSC is achieved [40, 41]. In a
retrospective review of patients with ROC treated in the CALYPSO trial [52], complete surgical
cytoreduction was associated with improved survival compared to patients treated with che-
motherapy alone; however, as patients who had less favourable features and who did not have
complete cytoreduction derived notably less benefit from surgery, then, as noted by the authors,
Surgery for Recurrent Ovarian Cancer
http://dx.doi.org/10.5772/intechopen.71587
281
there is likely to be a significant selection bias in the surgical studies on ROC [52]. Most reports
have not addressed quality of life (QoL) issues, but in one report [27], no difference was found to
be in QoL in patients with ROC who had chemotherapy alone and those who had surgery and
chemotherapy.
6. SCS in platinum-resistant recurrent ovarian cancer
This subgroup of patients has a poor prognosis and more recently bevacizumab has been used
as part of second-line treatment. With the associated operative morbidity and possible nega-
tive impact on QoL of major surgery in these patients, there has been understandable reluc-
tance both from surgeons and patients to undertake surgery. Where there has been initial
suboptimal cytoreduction the surgical goal of complete CSC is rarely achieved, if one extrap-
olates from the results of Rose et al. [53] in primary disease. A key finding in that study was the
training and skill of the surgeon who performed the primary surgery—a gynaecological
oncologist whose goal was complete cytoreduction, or a non-specialist surgeon. Case selection
for surgery in ROC is also influenced by the patient’s performance status, the number of and
sites of metastasis and in these cases obtaining the operative report from the initial surgery is
often instructive. The practice in the UK is more towards non-surgical management of recur-
rent disease in platinum-resistant cases. A more common clinical situation is the patient with
persistent but stable disease after primary treatment, in whom the disease progresses. In these
patients, elective surgery with the goal of achieving complete clearance of disease is most
unlikely to be achieved if the original surgery by a gynaecological oncologist was suboptimal
and in such cases the recommended treatment is second-line chemotherapy.
Nevertheless, there are some patients who were disease free at completion of treatment for
primary disease and have recurrent disease at one or a few sites within 6 months of completing
treatment and in whom secondary cytoreductive surgery may be an option [41, 54, 55] and
may enhance the otherwise limited response to chemotherapy. Whether or not there is a role
for initial laparoscopic assessment is unclear and practices vary. Treatment alternatives must
be discussed including palliative care [15]. In other clinical situations, a decision may be made
to operate on a patient to remove a large mass that is symptomatic even if CSC cannot be
achieved or warranted.
A less common EOC is the low grade serous carcinoma, which typically is less chemosensitive
and runs a more indolent course than the high grade serous carcinoma. Often in recurrent
disease, there is calcification which can render surgical resection more difficult. Given these
usual clinical features there more often is recourse to secondary cytoreductive surgery [56].
This is an individual decision and the pace of growth of the tumour site(s) and whether or not
the patient is symptomatic are important considerations.
7. Chemotherapy or surgery as initial treatment for ROC
In an early study [43], a less favourable outcome from secondary surgical cytoreduction was
reported if this was preceded by second-line chemotherapy. This was not found in a later
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study [56] on a small number of patients. However, if second-line chemotherapy has been
given and there has been disease progression, in general there would be a greater reluctance to
operate. This sequence of management of initial chemotherapy has been proposed as a means
to case select for secondary cytoreduction as only those showing a response should undergone
surgery. Bulky disease has been considered an adverse factor in those undergoing surgery for
ROC, but only in a few reports; Eisenkop et al. [43, 44] reported on patients with tumour mass
more than and less than 10 cm and Onda et al. reported [45] a poorer outcome from surgery
with tumour masses greater than 6 cm. Perhaps not surprising that amongst all patients
treated initially with chemotherapy for ROC, those who do better are those who also have
more favourable factors for surgery—such as longer DFI, good performance status and small
volume disease. As with surgery, predictive models for response and outcome for patients
treated with chemotherapy for ROC have been described. In the model proposed by Lee et al.
[22], CA125 level (≤ 100 IU/l or > 100 IU/l) was assessed as was largest tumour size (<5 cm
or >5 cm) but the role of secondary cytoreductive surgery was not assessed. Different manage-
ments of ROC may be appropriate in a particular patient but in patients with favourable
factors, secondary cytoreductive surgery (with or without chemotherapy) results in a better
outcome (overall survival) than chemotherapy alone [24, 30, 33], although level I evidence on
overall survival benefit is awaited [49]. In a large retrospective study on ROC in which patients
were treated with chemotherapy alone or with cytoreductive surgery and chemotherapy, the
latter group had improved overall survival, but only in those with no residual disease or
smaller volume residual disease [57].
8. Surgery and IP/HIPEC chemotherapy for recurrent ovarian cancer
The Cochrane review on the use of intraperitoneal (ip) chemotherapy for primary OC [58]
concluded that this treatment prolonged PFS and OS. While there is evidence of a survival
benefit for IP chemotherapy/HIPEC after cytoreductive surgery in primary disease, there are
fewer reports on its use and efficacy in recurrent disease [59]. No mention was made of this
type of treatment in the Cochrane review on recurrent ovarian cancer [60] nor in the review by
the Fifth Ovarian cancer Consensus Conference of the Gynecologic Cancer InterGroup [7].
Boisen et al. [61] reported on a retrospective study of 25 patients treated with iv/ip chemother-
apy but without secondary cytoreductive surgery. The study period was over 6 years on a
selected group of patients and 10 of 25 had an improved treatment-free interval. In a feasibility
study of ip chemotherapy in 56 patients with platinum-sensitive recurrent disease all of whom
had had prior secondary cytoreductive surgery (67.9% to <1 cm), 79% tolerated 6 cycles of ip
platinum. No difference in outcome was noted related to the completeness of secondary
surgery and the median overall survival was 51 months; no clinical factors associated with
improved PFS or OS were identified [62]. The data from other studies report that the main
indicators for response to ip chemotherapy are (1) volume of residual disease and (2) platinum-
sensitive disease [63, 64]. Fujiwara, in contrast reported responses in patients with suboptimal
surgical resection [65].
Ansaloni et al. [66] provided one of the first reports on HIPEC following cytoreductive surgery
in 30 patients with recurrent disease. In this small study, HIPEC was considered safe and there
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was a trend to improved survival with complete cytoreduction and HIPEC. A more recent
study [67] reported a survival benefit in what they described as randomised trial on the use of
HIPEC in recurrent ovarian cancer. However, there were a number of deficiencies in study
design and questions were raised about the validity of the results and the efficacy of HIPEC as
reported in that study [68]. In another retrospective review [69], Cripe et al. reported on 32
patients that CRS and HIPEC were feasible. However, they also noted 65.6% grade 3 or 4
toxicity (morbidity) and that troublesome pleural effusions were associated with diaphragmatic
stripping and/or resection. As a number of chemotherapeutic agents were used with varying
dwell times and temperatures, it is unclear what regimen to recommend. As with primary
disease, a key component in the use of HIPEC is complete cytoreduction or minimal residual
disease (<5 mm deposits). A recent report on a retrospective cases series from China on 46
patients with advanced (n = 16) or recurrent (n = 30) ovarian cancer reported a survival benefit
with HIPEC but only when there was complete surgical cytoreduction [70]. However, the
adjuvant treatment included iv/ip chemotherapy and it is not clear what contribution HIPEC
and ip chemotherapy made to improved survival. In contrast, in a study on secondary
cytoreductive surgery in EOC, 50 patients underwent surgery only and 29 also had HIPEC,
although there were no deaths in the latter group and two in the former group, the addition on
HIPEC did not confer an advantage on median disease-free survival [71]. Data were not
presented, however, on overall survival or disease-specific survival. In a larger retrospective
multi-centre Italian study on 226 patients with primary ovarian cancer and 285 with ROC
treated over 16 years, HIPEC was of benefit in patients with ROC who had had complete
surgical resection and platinum-sensitive disease [72]. In a large French study of HIPEC in
primary and recurrent ovarian cancer, no difference was noted in overall survival between
patients with platinum-sensitive and platinum-resistant disease and the main prognostic factor
for survival and DFI was the extent of disease, or tumour burden, as measured on the peritoneal
cancer index [73]. In the studies showing benefit of CSC and HIPEC, it is still unclear what, if
any, additional benefit HIPEC can achieve over CSC. There is still ongoing debate about the role
of HIPEC, with the view that HIPEC should be offered only in clinical trials [74]. In fact a
number of trials of ip chemo and HIPEC in recurrent ovarian cancer are recruiting [75].
9. Recurrent ovarian cancer outside the abdomen and pelvis
With the improvement in overall survival in ovarian cancer, and better understanding of
cancer genetics, targeted therapies and improved surgery, it is now more common to see
patients with unusual or atypical sites of recurrent disease [76]. Sites include breast, brain,
bone (including vertebral spine), chest wall, skin (other than port site metastasis) and lymph
nodes such as the axillary nodes [77–79]. Given the unusual location of metastasis it is impor-
tant to exclude other sites of disease and commonly PET-CT is used. Biopsy is often necessary
to exclude another cancer. In contrast, histologic confirmation of recurrent OC in the pelvis
and/or abdomen is not usual clinical practice. Management of the recurrence will include
general supportive measures such as pain relief, radiotherapy (e.g. with vertebral metastasis)
and chemotherapy, trial drugs and specialised surgery, for example, neurosurgery. The surgery
may be indicated for symptom relief and may be considered necessary, even life-saving, in the
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presence of metastatic disease at other sites. In assessing the role of specialised surgery for
recurrent metastatic ovarian cancer, factors to be considered include—morbidity of surgery,
likelihood of resecting disease, likelihood of palliating symptoms by surgical resection, and the
patient’s prognosis, with and without surgery. There is also some evidence that patients
treated with IP chemotherapy and then subsequently with bevacizumab have a greater pro-
pensity to develop unusual sites of metastastic recurrence [80]. Patients with a BRCA mutation
compared to those who do not have a BRCA mutation more often develop unusual sites of
recurrence.
10. Recurrent ovarian cancer and bowel obstruction
Most patients with EOC present with advanced stage disease and most will develop recur-
rence. A common presentation of recurrent disease is relapsing and remitting bowel obstruc-
tion, the course of which is more often chronic than acute [81, 82]. Invariably the development
of bowel obstruction indicates recurrent (or progressive) disease, even if the tumour markers
are not elevated and there is no radiological evidence of disease. The management is conser-
vative, at least initially with fasting, intravenous fluids and pharmacological manipulation [81,
82]. Involvement of the palliative care team is important. Surgical intervention is associated
with significant morbidity and mortality and not all patients, perhaps only about two-thirds
benefit from surgery in terms of resumption of adequate oral intake. Despite this common
problem in recurrent ovarian cancer, QoL data on surgical and non-surgical intervention are
notably absent from most reports.
Surgical intervention includes—placement of a gastrostomy tube [83], by pass procedures, but
most often formation of a diverting stoma. As the disease is often more extensive in the pelvis
with serosal and mesenteric disease, more often an ileostomy is raised rather than a colostomy,
although often when a loop ileostomy is performed it is necessary to defunction the large
bowel by raising a mucous fistula. If a recto-vaginal fistula develops from extensive pelvic
disease, a colostomy may provide successful palliation but typically to a limited extent. That is,
the patient will continue to have other problems related to the pelvic disease—including pelvic
pain, discharge and vaginal or rectal bleeding. It is important to discuss with the patient the
likely palliative benefit of surgery, as it is to discuss the outcomes from the surgical and non-
surgical management of bowel obstruction.
11. Surgery for second recurrence and beyond
There are fewer reports on the role of surgery for second, third, etc. relapse of EOC. Intuitively
the factors that are important in surgical decision making for first recurrence should also be
important in surgical decision making in patients with second and subsequent recurrence. It is
clear too that if surgery is contemplated for such relapses the patients are highly selected and
more often than not surgical intervention will be for palliation (e.g. bowel obstruction) rather
than for complete cytoreduction. More usually in clinical practice patients with second and
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subsequent relapse will be treated with chemotherapy or other drug therapy. The paucity of
cases and reports on tertiary cytoreduction emphasises the uncommon clinical scenario of a
patient with second relapse of EOC undergoing surgery. In a multi-centre retrospective review
of 406 patients [84], based over a 16-year period, it was reported that residual tumour after
secondary and tertiary surgery was an important prognostic factor and surgical outcome was
compromised by ascites and upper abdominal disease. Avras et al. [85] reported that the
surgical goal, as with first recurrence, should be complete cytoreduction as this improved
overall survival. The usual factors to be considered for surgery in recurrent disease with the
goal of complete cytoreduction, such as disease-free interval, were reported but they also
found an association with increased size of recurrent disease and reduced benefit from surgery.
Another report highlighted the importance of case selection and maximixing cytoreduction
[86]. No QoL data were presented in these papers.
12. Recurrent non-epithelial ovarian cancer
Most reports on ROC almost exclusively deal with epithelial ovarian cancer. Even with the
EOC, the subgroup of mucinous cancers, which are less chemosensitive than their serous
counterparts, arguably should more often be treated with surgery for first recurrence than
with chemotherapy. The recent Gynecologic Cancer Intergroup (GCIG) report provided little
guidance [87]. Two reports describe a very poor outcome when mucinous ovarian cancers
relapse and caution about surgical intervention [88, 89]. It remains unclear whether recurrent
mucinous cancer should be managed as recurrent pseudomyxoma peritoneii with extensive
peritoneal resection and HIPEC.
There are fewer reports on the less common OC subtypes. Granulosa cell tumours, which have
limited chemosensitivity compared to EOC typically have an indolent course. Whereas primary
disease is often of low stage, recurrent disease is characterised by multi-site relapse which
presents different surgical challenges if complete cytoreduction is the goal [90]. Given their more
indolent behaviour there may be an argument for targeting symptomatic masses rather than
CSC. For germ cell tumours, most of the information is extrapolated from data on male patients.
Germ cell tumours are rare in females and the immature teratoma, defined by the presence of
immature cancerous tissue, most often immature neural tissue, typically is managed by chemo-
therapy after initial surgery. Two conditions described in the literature on germ cell tumours are
the “growing teratoma syndrome” and “chemotherapeutic retroconversion” are generally con-
sidered to be the same as histologically the tissue found is mature teratoma [91]. In the former,
after successful chemotherapy, there is recurrent disease but of mature not immature teratoma; in
the latter, chemotherapy given to immature teratoma resulted in subsequent mature elements
only. This is important to recognise as otherwise disease-progression or recurrence (of original
immature disease) is diagnosed. If further immature teratoma is diagnosed after primary treat-
ment this is associated with a less favourable prognosis and pathological confirmation of recur-
rence as mature or immature is necessary to appropriately manage. Typically treatment of
recurrent disease is conservative surgery and further chemotherapy [92]. The specific consider-
ations are the young age of patients and fertility preservation, chemosensitivity and the growing
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teratoma syndrome. Themore usual indication for surgery is to remove a symptomatic mass or a
growing mass that is causing pressure symptoms (the growing teratoma syndrome). In such
cases, the focus of surgery in the typical young patient, with fertility preservation necessary, is
not complete cytoreduction but resection of the symptomatic mass. A less common clinical
problem is of peritoneal disease with mature glial tissue—gliomatosis peritoneii, which most
often has a very indolent course. Typically the initial primary surgery has been fertility preserv-
ing. With relapsed disease, which may be in the pelvis or disseminated, including involvement
of the retroperitoneal lymph nodes, it is important to determine whether the relapsed disease is
mature or immature teratoma, and although both pathologies may be present the more common
is mature teratoma [93]. For gliomatosis peritoneii, which is of different grades, surgery should
be in symptomatic patients only, the goal is palliation and not complete cytoreduction, which is
most often not feasible. When secondary surgery is undertaken for recurrent disease the repro-
ductive organs should be preserved if possible (including the uterus). The surgical goal is
cytoreduction with fertility preservation, and it is reasonable to leave small volume disease on
the one remaining ovary.
13. Conclusion
Most patients with OC present with late stage disease and most are destined to develop
recurrence and to die of disease. Consideration needs to be given as to how recurrence is
diagnosed and whether the patient is asymptomatic or symptomatic. The majority of data on
ROC is from studies on EOC, but the role of secondary surgery is influenced by the histologic
subtypes of OC. Patients treated with second-line chemotherapy tend to have less favourable
features than those treated initially with surgery. In non-randomised studies, where there is
likely selection bias, usually showed a benefit in overall survival from secondary cytoreductive
surgery compared to chemotherapy alone. Consistently non-randomised studies report that
the benefit of surgery in terms of DFI and survival is seen only in patients with complete
surgical cytoreduction. Only one of three current randomised trials has reported preliminary
data which show a benefit from surgery and data on overall survival are awaited. As complete
surgical cytoreduction at primary surgery is an important factor in improved outcome from
primary treatment and from secondary treatment, patients with primary OC should be man-
aged in specialist units where complete cytoreduction is achieved in the majority of patients.
There may be a benefit from ip chemotherapy or HIPEC following cytoreductive surgery for
ROC but level one evidence is needed.
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